RV521
Small moleculeexperimental
Clinical trial activity
15 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 30, 2017 (NCT03258502)
Timeline
Indications
Mechanism of action
- RSV F-proteinINHIBITOR
RSV F-protein inhibitor
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F- Mol. weight
- 446.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297497 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06079320 | Phase 2/Phase 3 (Phase 3) | Dec 5, 2023 | Pfizer |
| NCT06105983 | Phase 1 | Nov 3, 2023 | Pfizer |
| NCT05987072 | Phase 1 | Nov 3, 2023 | Pfizer |
| NCT06037031 | Phase 1 | Oct 30, 2023 | Pfizer |
| NCT05994963 | Phase 1 | Sep 1, 2023 | Pfizer |
| NCT06003829 | Phase 1 | Jul 31, 2023 | Pfizer |
| NCT05857644 | Phase 1 | Jun 9, 2023 | Pfizer |
| NCT05878522 | Phase 1 | May 15, 2023 | Pfizer |
| NCT05712460 | Phase 1 | Feb 8, 2023 | Pfizer |
| NCT05873764 | Phase 1 | May 25, 2022 | Pfizer |
| NCT04267822 | Phase 2 | Feb 29, 2020 | ReViral Ltd |
| NCT04225897 | Phase 2 | Nov 13, 2019 | ReViral Ltd |
| NCT04065698 | Phase 1 | Aug 13, 2019 | ReViral Ltd, Richmond Pharmacology |
| NCT03782662 | Phase 1 | Nov 6, 2018 | ReViral Ltd, Richmond Pharmacology |
| NCT03258502 | Phase 2 | Jul 30, 2017 | ReViral Ltd |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 10 | 10 | 2 | 2022 |
| ReViral Ltd | For profit | 5 | 5 | 2 | 2017 |
| Richmond Pharmacology | For profit | 2 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1